NIH unit grants XOMA $65M to work on botulism treatment

09/10/2008 | American City Business Journals

The National Institute of Allergy and Infectious Diseases awarded XOMA a $65 million contract to develop a treatment for botulism, a potentially lethal disease caused by a neurotoxin from the bacterium Clostridium botulinum. XOMA intends to begin trials next year for its first antibody product against the disease.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC